How RecursiveMAS speeds up multi-agent inference by 2.4x and reduces token usage by 75%

UIUC and Stanford's RecursiveMAS lets AI agents collaborate in embedding space instead of text, cutting token usage by 75% ...

Notable Researchers Join $4 Billion Effort to Build Self-Improving A.I.

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate ...
Forbes

OpenAI Boasts Recursive AI: 3 Examples

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...
Forbes

The Most Important Idea In AI: Recursive Self Improvement

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
Seeking Alpha

Recursion jumps after solid Q4 beat

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Seeking Alpha

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Reuters

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...
The Motley Fool

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock

Recursion Pharmaceuticals doesn't have any products on the market. In fact, none of the company's candidates are currently in phase 3 studies. So, despite the biotech's claims that its AI-powered ...
STAT

Recursion CEO Chris Gibson out as company head after 12 years

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...